期刊
EXPERT REVIEW OF VACCINES
卷 14, 期 11, 页码 1471-1478出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/14760584.2015.1083429
关键词
adenovirus; dendritic cells; Ebola; HIV; immune complex; pre-existing immunity
类别
资金
- European Community's 7th Framework Program (BrainCAV) [222992]
- European Community's 7th Framework Program (BrainVectors) [286071]
- European Community's 7th Framework Program (ADVance) [290002]
- French Agence National de la Recherche
- Fondation de France
- University of Science and Technology of Ha Noi
- E-Rare
In 2014, an outbreak of Ebola virus spread rapidly in West Africa. The epidemic killed more than 10,000 people and resulted in transmissions outside the endemic countries. WHO hopes for effective vaccines by the end of 2015. Numerous vaccine candidates have been proposed, and several are currently being evaluated in humans. Among the vaccine candidates are vectors derived from adenovirus (Ad). Despite previous encouraging preclinical and Phase I/II trials, Ad vectors used in three Phase II trials targeting HIV were prematurely interrupted because of the lack of demonstrated efficacy. The vaccine was not only ineffective but also led to a higher rate of HIV acquisition. In this context, the authors discuss the potential benefits, risks and impact of using Ad-derived vaccines to control Ebola virus disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据